AKAneta Kopacz

Aneta Kopacz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aneta Kopacz has a total of 141 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hepatits E virus (HEV) as a new challenge in Poland based on narrative review of epidemiological and clinical data

    by Piotr Grabarczyk, Aleksandra Kalińska, Aneta Kopacz, Ewa Sulkowska, Anna Parfieniuk-Kowerda, Jerzy Jaroszewicz

    Manuscripts on hepatitis E virus (HEV) epidemiology in Poland listed in Pubmed were analyzed in the context of current clinical and biological knowladge and epidemiological data from other regions of Europe and the world. Analyzed data indicates a high frequency of IgG HEV in Poland compared to other European countries and parts of the world, on average it exceeds 40%. In some regions of the country, even near 60% of the population has been passed infection. It has been estimated based on the frequency of acute phase markers, that at least 113,000 residents may be infected each year. Presented results encourage to improve availability of HEV diagnostics, to increase of physicians’ awareness and taking into account HEV infection as an etiological factor of numerous diseases. Preventive measures, especially in risk groups and research on the clinical significance of HEV and on effective therapeutic management should be considered.

  • Open Access

    Performance evaluation of Procleix® UltrioPlex E® Assay for multiplexed automated NAT screening of blood donors for HCV, HIV, HBV, HEV and recommendation in case of HEV detection in donors

    by Aneta Kopacz, Dorota Kubicka-Russel, Grzegorz Liszewski, Magdalena Gudzińska-Adamczyk, Jolanta Gdowska, Anna Parfieniuk-Kowerda, Ewa Sulkowska, Magdalena Łętowska, Xiaomei Zhu, Piotr Grabarczyk

    Background: The Procleix UltrioPlex E assay for use with the Procleix Panther is a qualitative test applying the TMA method, for the detection of HCV RNA, HBV DNA, HEV RNA and HIV-1 RNA in human plasma and serum. The assay simultaneously identifies HIV, HCV, HEV and HBV (multiplex). An optional component of the system is the Procleix Xpress instrument that creates pools from individual samples. Aim: To evaluate the Procleix UltrioPlex E assay in individual donations and in plasma pools using the Procleix Xpress instrument. Material and methods: Analytical sensitivity was assessed with serial dilutions of the WHO International Standards (IS): HCV, HIV-1, HBV (NIBSC) and International Standard for Hepatitis E Virus (PEI). Correct identification of reactive donations, clinical sensitivity and the risk of contamination were tested in two formats: individually (IDT) and in pools of 4 donations (MP4). In each format 193 negative and 7 reactive donations — 4 with HCV, HIV, HBV or HEV and 3 samples with co-infection (HEV+HCV, HEV+HIV or HEV+HBV) were tested. Additionally, 20 plasma samples from living cells, tissue and organ donors (Hematopoietic stem-cell transplantation donors, HSCT) were examined. Results: 95% Limits of detection (with 95% confidence interval) for Procleix UltrioPlex E assay were 4,0 IU/mL (2,8–12,0), 2,9 IU/mL (1,9–8,7), 66,8 IU/mL (40,8–159,3) and 5,5 IU/mL (4,0–11,2) for HCV, HBV, HIV-1 and HEV respectively. Due to the lower sensitivity for HIV-1 RNA obtained in the assay evaluation compared to the manufacturer’s instruction (4th IS WHO 16/194 was used in both laboratories), additional tests of the BioQControl P0290 HIV-1 RNA subtype B panel, which was calibrated to 2nd IS WHO 97/650, were performed. Probit analysis of the tested BioQControl panel demonstrated an analytical sensitivity of 17.9 IU/mL (95% LOD) for HIV-1 RNA. During the simulation of screening in individual donations, correct identification of HIV/HCV/HBV and HEV infections and co-infections was found. In the tested mini-pools created with the Procleix Xpress System, infected donations were also correctly detected. There were no false negative or false reactive results during the evaluation. Conclusions: The Procleix UltrioPlex E assay on the Procleix Panther System, including the Procleix Xpress instrument, demonstrated high sensitivity and satisfactory specificity required by the Polish blood donation system. The Procleix UltrioPlex E assay correctly identified infected donations without false results. Differences in the ability to detect HIV-1 RNA in sample dilutions when using the 4th WHO HIV-1 Standard (16/194) and BioQControl P0290 HIV-1 RNA subtype B (calibrated to 97/650) may be caused by heat-inactivation of the first reference material applied during manufacturing. In case of assay implementation, since international guidelines are not available the authors proposed a country recommendation on HEV screening, management of infected donors and donations and HEV infection reporting should be introduced. Keywords: RNA HEV RNA HCV DNA HBV RNA HIV donor screening recommendation evaluation multiplex NAT

  • Open Access

    Charakterystyka Procleix®UltrioPlex E® Assay — testu multiplex przeznaczonego do automatycznego badania dawców krwi w kierunku HCV, HIV, HBV, HEV oraz zalecenia postępowania w przypadku wykrycia HEV u dawcy

    by Aneta Kopacz, Dorota Kubicka-Russel, Grzegorz Liszewski, Magdalena Gudzińska-Adamczyk, Jolanta Gdowska, Anna Parfieniuk-Kowerda Parfieniuk-Kowerda, Ewa Sulkowska, Magdalena Łętowska, Xiaomei Zhu, Piotr Grabarczyk

    Background: The Procleix UltrioPlex E assay for use with the Procleix Panther is a qualitative test applying the TMA method, for the detection of HCV RNA, HBV DNA, HEV RNA and HIV-1 RNA in human plasma and serum. The assay simultaneously identifies HIV, HCV, HEV and HBV (multiplex). Optional component to the system is the Procleix Xpress instrument that creates pools from individual samples. Aim: To evaluate the Procleix UltrioPlex E assay in individual donations and in plasma pools using the Procleix Xpress instrument. Material and Methods: Analytical sensitivity was assessed with serial dilutions of the WHO International Standards (IS): HCV, HIV-1, HIV-2, HBV (NIBSC) and International Standard for Hepatitis E Virus (PEI). Correct identification of reactive donations, clinical sensitivity and the risk of contamination were tested in two formats: individually (IDT) and in pools of 4 donations (MP4). In each format 193 negative and 7 reactive donations - 4 with HCV, HIV, HBV or HEV and 3 samples with co-infection (HEV+HCV, HEV+HIV or HEV+HBV) were tested. Additionally, 20 plasma samples from organ and tissue donors (Hematopoietic stem-cell transplantation donors, HSCT) were examined. Results: 95% Limits of detection (with 95% confidence interval) for Procleix UltrioPlex E assay were 4,0 IU/mL (2,8-12,0), 2,9 IU/mL (1,9-8,7), 66,8 IU/mL (40,8-159,3) and 5,5 IU/mL (4,0-11,2) for HCV, HBV, HIV-1 and HEV respectively. Due to the lower sensitivity for HIV-1 RNA obtained in the assay evaluation compared to the manufacturer's instruction (4th IS WHO 16/194 was used in both laboratories), additional tests of the BioQControl P0290 HIV-1 RNA subtype B panel, which was calibrated to 2nd IS WHO 97/650, were performed. Probit analysis of the tested BioQControl panel demonstrated an analytical sensitivity of 17.9 IU/mL (95% LOD) for HIV-1 RNA. During the simulation of screening in individual donations, correct identification of HIV/HCV/HBV and HEV infections and co-infections was found. In the tested mini-pools created with the Procleix Xpress System, infected donations were also correctly detected. There were no false negative or false reactive results during the evaluation. Conclusions: The Procleix UltrioPlex E assay on the Procleix Panther System, including the Procleix Xpress instrument demonstrated high sensitivity and satisfactory specificity required by the Polish blood donation system. The Procleix UltrioPlex E assay correctly identified infected donations without false results. Differences in ability to detect HIV-1 RNA in sample dilutions when using the 4th WHO HIV-1 Standard (16/194) and BioQControl P0290 HIV-1 RNA subtype B (calibrated to 97/650) may be caused by heat-inactivation of the first reference material applied during manufacturing. In case of assay implementation, since international guidelines are not available we proposed a country recommendation on HEV screening, management of infected donors and donations and HEV infection reporting should be introduced. Keywords: RNA HEV RNA HCV DNA HBV RNA HIV donor screening recommendation evaluation multiplex NAT

  • Open Access

    Hepatitis B Virus in Polish Blood Donors in the Period 2005–2019—Significant Changes in Epidemiology and Demographic Characteristics of Infected Donors

    by Aneta Kopacz, Dorota Kubicka-Russel, Grzegorz Liszewski, Ewa Sulkowska, Anna Chrzanowska, Paulina Zwolińska, Ewa Noceń, Anna Potępa, Magdalena Łętowska, Piotr Grabarczyk, et al.

    In the 1980s, Poland was a medium-endemic country, with one of the highest incidences of hepatitis B in Europe (45/105 inhabitants). Pursuant to the WHO guidelines, obligatory vaccination was introduced in 1994–1996 (as a part of hepatitis B prophylaxis for newborns), and in 2000–2011, all 14-year-olds were vaccinated. To prevent transfusion-transmitted HBV infection (TT-HBV), since the 1970s, each donation has been tested for HBsAg and, since 2005, additionally for the presence of HBV DNA. Based on the data from the Blood Transfusion Centers, changes in HBV detection in Polish blood donors were analyzed, starting from the introduction of mandatory NAT screening until 2019. During the period under analysis, a total of 11,625 HBV-infected donors were identified: 97.95% were seropositive (confirmed HBsAg) and 2.05% were seronegative (NAT yields). The detection frequency for both categories of infections was significantly (p = 0.05) higher for men than for women (Residual Risk RR = 1.4 and RR = 2.63, respectively). Seropositive infections were detected more frequently (p < 0.05) in first-time donors than in repeat donors (RR = 360), while no significant differences were observed in the category of seronegative infections. A downward trend in HBsAg detection was observed in both first-time and repeat donors (Spearman’s coefficient R = −0.98 and R = −0.90, respectively). The frequency of HBsAg in first-time donors decreased 5-fold, and, in repeat donors, 30-fold. In both subpopulations, the largest decrease occurred in the age group ≤ 20 years (i.e., donors born between 1985 and 2001). The incidence of window period (WP) infections in the repeat donor group demonstrated a downward trend (R = −0.54, p < 0.05), and in the first-time donor group, no significant trend was recorded. For occult hepatitis B infection (OBI), no significant trend was observed in either donor subpopulation. WP infections were detected significantly more often in donors aged 21–50 years than in donors ≤20 years, most often in the 41–50 age group. The frequency of OBI increased with donor age and was the highest in the 51–60 age group. A spectacular decrease in the frequency of HBsAg(+) infections was observed in current study, indicating the effectiveness of the hepatitis prevention strategy applied in Poland. We expect that the improvement in the epidemiological situation among blood donors causes a reduction in the risk of TT-HBV. Confirmation of this hypothesis by the analysis of residual risk should be a subject of further studies.


  • Open Access

    Seronegative hepatitis C virus infection in Polish blood donors—Virological characteristics of index donations and follow‐up observations

    by Piotr Grabarczyk, Dorota Kubicka‐Russel, Aneta Kopacz, Grzegorz Liszewski, Ewa Sulkowska, Paulina Zwolińska, Kazimierz Madaliński, Maciej Marek, Małgorzata Szabelewska, Ewa Świątek, et al.

    Nucleic acid testing (NAT) was implemented in Poland in 1999 for screening of plasma for fractionation and for all blood donors in 2002. To analyze seronegative NAT‐positive samples representing hepatitis C virus (HCV) window‐period (WP) in the years 2000 to 2016 and to determine infection outcome. We analyzed results of 17 502 739 donations screened in minipools (6‐48) or individually. Index samples underwent viral load (VL) quantification, genotyping and Ag, and anti‐HCV re‐testing using chemiluminescence (CMIA), electrochemiluminescence (ECLIA), and fourth‐generation enzyme‐linked immunosorbent assay (IV EIA) assays. HCV‐seronegative infections were identified in 126 donations (7.2/mln donations; 95% confidential intervals, 6.0‐8.6). Frequency of NAT yields was decreasing over time. Of the initial 126 seronegative index cases 106 were retested: 32.1% were reactive in IV EIA, 11.3% in ECLIA, and 1.9% in CMIA. The lowest VL correlated with absent anti‐HCV and HCV Ag, while VL was highest when the antigen was detectable and then it decreased when anti‐HCV appeared at a level detectable by sensitive third generation tests while retesting. The proportion of genotype 1 was 38.9% in samples positive only for HCV RNA and 71.4% in samples that were anti‐HCV reactive in re‐testing. In parallel, genotype 3 frequency was 50% in the former group and 21% in the latter. NAT is an effective measure to limit HCV transmission by transfusion and IV EIA seems to have higher clinical sensitivity than ECLIA. Samples representing likely successive phases of early HCV infection were characterized by different genotype distribution probably due to very early elimination of genotype 3.


  • International Forum on Occult hepatitis B infection and transfusion safety

    by Clive R. Seed, Jean‐Pierre Allain, Miquel Lozano, Syria Laperche, Pierre Gallian, Sylvie Gross, So‐Yong Kwon, E.Y. Oh, J.N. Kim, Sze Sze Chua, et al.


  • International forum on Occult hepatitis B infection and transfusion safety

    by Clive R. Seed, Jean‐Pierre Allain, Miquel Lozano, Syria Laperche, Pierre Gallian, Sylvie Gross, So‐Yong Kwon, Eun Young Oh, Jun Nyun Kim, Sze Sze Chua, et al.


  • Molecular and serological infection marker screening in blood donors indicates high endemicity of hepatitis E virus in Poland

    by Piotr Grabarczyk, Ewa Sulkowska, Jolanta Gdowska, Aneta Kopacz, Grzegorz Liszewski, Dorota Kubicka‐Russel, Sally A. Baylis, Victor M. Corman, Ewa Noceń, Dariusz Piotrowski, et al.

    BACKGROUND: Until now, markers of hepatitis E virus (HEV) infection have not been studied in blood donors throughout Poland, and no acute case of HEV infection has been closely documented or confirmed by HEV RNA detection. The prevalence of HEV infection markers, including HEV RNA in Polish blood donors and virus genotypes was investigated.STUDY DESIGN AND METHODS: In total, 12,664 individual donations from 22 Polish blood transfusion centers were tested for HEV RNA by transcription‐mediated amplification. In addition, 3079 first‐time donors sampled throughout Poland also were screened for antibodies to HEV. HEV RNA and immunoglobulin M‐positive donations were confirmed using real‐time reverse transcription‐polymerase chain reaction and Western blotting, respectively.RESULTS: Ten donors were identified as RNA initial reactive (one of 1266 donors), and six (one of 2109) were identified as repeat reactive and confirmed by real‐time reverse transcription‐polymerase chain reaction or seroconversion. Sequence analysis identified HEV Genotype 3c in one donor and Genotype 3i in two others. On average, 43.5% of donors were immunoglobulin G‐positive. Immunoglobulin G seroprevalence ranged from 22.7% to 60.8% in group ages 18 to 27 years and 48 to 57 years, respectively and differed between administrative regions from 28.9% in Podlasie to 61.3% in Wielkopolska. Thirty‐nine of the donors were immunoglobulin M‐positive, and seven donors were IgM positive only (0.2%). Of 37 immunoglobulin M‐reactive samples tested by Western blot, 24 (64.9%) were confirmed.CONCLUSIONS: The current results indicate a high level of HEV endemicity throughout Poland compared with other countries. There is an urgent need to consider the protection of recipients of blood components against transfusion‐transmitted HEV infection.


  • Ryzyko przeniesienia czynników zakaźnych przez transfuzje w Polsce

    by Piotr Grabarczyk, Aneta Kopacz, Ewa Sulkowska, Aleksandra Kalińska